<DOC>
	<DOCNO>NCT01063725</DOCNO>
	<brief_summary>The purpose study test effect Femarelle ( plan-derived SERM ) hot flush quality life menopausal woman . Our hypothesis compare placebo , Femarelle reduce daily number hot flush severity also improve quality life measure validated dairy questionnaire .</brief_summary>
	<brief_title>A Double-Blind Study Evaluate Effect FemarelleÂ® Menopausal Vasomotor Symptoms</brief_title>
	<detailed_description>Symptomatic menopausal woman divide treatment Femarelle placebo 12 week two week baseline record . Hot flash daily diary record daily quality life questionnaire fill begin completion study .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<criteria>1. postmenopausal woman , i.e 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/ 2 . More 7 hot flush per day 50 per week baseline . 3 . Women documentation negative screening mammogram ( obtain screen within 1 year study enrolment . 4 . Normal pelvic breast exam investigator prior enrolment . 5 . All subject uterus endometrial thickness le 5mm vaginal sonogram exam randomization . 6 . Informed consent participate study . 1 . Use medication supplement menopausal symptom , estrogen/progestin contain drug product , Isoflavons , phytoestrogens SERM within minimum 8 week prior prestudy screen period . 2 . Use SSRIs , St. John 's Wort , within minimum 8 week prior prestudy screen period . 3 . Any clinically unstable uncontrolled renal , hepatic , endocrine , respiratory , hematological , neurological , cardiovascular cerebrovascular disease would put subject safety risk mask measure efficacy 4 . Evidence history vascular disease ( ischemic heart disease ) , Cerebrovascular accident ( stroke transient ischemic attack ) deep vein thrombosis ( blood clot ) , thromboembolic disorder . 5 . Personal history breast cancer 6 . Abnormal clinically relevant vaginal bleeding 7 . Any clinically relevant ( opinion investigator ) abnormal find physical , gynecological breast examination screen 8 . Abnormal , clinically significant result mammography 9 . Malignancy exception BCC skin 10 . Known hypersensitivity gluten , soybean , soy protein , estrogens and/or progestin 11 . History severe recurrent depression , severe psychiatric disturbance . Untreated uncontrolled high blood pressure ( hypertension ) 12 . Participation clinical trial within 30 day prior screen Known substance abuse ( alcohol drug ) 13 . Unable comply study protocol</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>menopause</keyword>
	<keyword>hot flash</keyword>
	<keyword>vasomotor symptom</keyword>
	<keyword>femarelle</keyword>
	<keyword>soy extract</keyword>
	<keyword>SERM</keyword>
</DOC>